249 related articles for article (PubMed ID: 18544951)
1. Usefulness of a new immunoradiometric assay of HCV core antigen to predict virological response during PEG-IFN/RBV combination therapy for chronic hepatitis with high viral load of serum HCV RNA genotype 1b.
Sasase N; Kim SR; Kim KI; Taniguchi M; Imoto S; Mita K; Hotta H; Shouji I; El-Shamy A; Kawada N; Kudo M; Hayashi Y
Intervirology; 2008; 51 Suppl 1():70-5. PubMed ID: 18544951
[TBL] [Abstract][Full Text] [Related]
2. Early decline of the HCV core antigen can predict SVR in patients with HCV treated by Pegylated interferon plus ribavirin combination therapy.
Fujino T; Nakamuta M; Aoyagi Y; Fukuizumi K; Takemoto R; Yoshimoto T; Miyahara T; Harada N; Sakai H; Nakashima M; Enjoji M
J Dig Dis; 2009 Feb; 10(1):21-5. PubMed ID: 19236543
[TBL] [Abstract][Full Text] [Related]
3. Pegylated interferon plus ribavirin combination therapy for chronic hepatitis C with high viral load of serum hepatitis C virus RNA, genotype 1b, discontinued on attaining sustained virological response at week 16 after onset of acute pancreatitis.
Kim SR; Imoto S; Mita K; Taniguchi M; Sasase N; Muramatsu A; Kudo M; Kitai S; El-Shamy A; Hotta H; Hayashi Y
Digestion; 2009; 79(1):36-9. PubMed ID: 19246919
[TBL] [Abstract][Full Text] [Related]
4. A matched case-controlled study of 48 and 72 weeks of peginterferon plus ribavirin combination therapy in patients infected with HCV genotype 1b in Japan: amino acid substitutions in HCV core region as predictor of sustained virological response.
Akuta N; Suzuki F; Hirakawa M; Kawamura Y; Yatsuji H; Sezaki H; Suzuki Y; Hosaka T; Kobayashi M; Kobayashi M; Saitoh S; Arase Y; Ikeda K; Kumada H
J Med Virol; 2009 Mar; 81(3):452-8. PubMed ID: 19152407
[TBL] [Abstract][Full Text] [Related]
5. The use of different Peg-interferon alpha-2b regimens plus ribavirin in HCV-1b-infected patients after rapid virological response does not affect the achievement of sustained virological response.
Napoli N; Giannelli G; Antonaci A; Antonaci S
J Viral Hepat; 2008 Apr; 15(4):300-4. PubMed ID: 18307592
[TBL] [Abstract][Full Text] [Related]
6. [Association between ribavirin plasma concentration and sustained virologic response in treatment of patients with genotype 1b chronic hepatitis C with pegylated interferon-α-2b and ribavirin].
Wang MR; Zhang X; Yang ZG; Li P; Gao L; Chen XH; Wang J; Xiong X; Wang SM; Geng JB; Hao KY; Xie F; Wang M; Zheng WK
Zhonghua Gan Zang Bing Za Zhi; 2016 Mar; 24(3):175-80. PubMed ID: 27095759
[TBL] [Abstract][Full Text] [Related]
7. Early viral kinetics and treatment outcome in combination of high-dose interferon induction vs. pegylated interferon plus ribavirin for naive patients infected with hepatitis C virus of genotype 1b and high viral load.
Tsubota A; Arase Y; Someya T; Suzuki Y; Suzuki F; Saitoh S; Ikeda K; Akuta N; Hosaka T; Kobayashi M; Kumada H
J Med Virol; 2005 Jan; 75(1):27-34. PubMed ID: 15543591
[TBL] [Abstract][Full Text] [Related]
8. Rapid virological response assessment by Abbott RealTime hepatitis C virus assay for predicting sustained virological responses in patients with hepatitis C virus genotype 1 treated with pegylated-interferon and ribavirin.
Su PY; Yen HH; Hsu YC; Wu SS; Kor CT; Su WW
Kaohsiung J Med Sci; 2016 Jul; 32(7):381-6. PubMed ID: 27450028
[TBL] [Abstract][Full Text] [Related]
9. Efficacy and safety of peg-IFN alfa-2a with ribavirin for the treatment of HCV/HIV coinfected patients who failed previous IFN based therapy.
Rodríguez-Torres M; Rodríguez-Orengo JF; Ríos-Bedoya CF; Fernández-Carbia A; González-Lassalle E; Salgado-Mercado R; Marxuach-Cuétara AM
J Clin Virol; 2007 Jan; 38(1):32-8. PubMed ID: 17064957
[TBL] [Abstract][Full Text] [Related]
10. Benefit of hepatitis C virus core antigen assay in prediction of therapeutic response to interferon and ribavirin combination therapy.
Takahashi M; Saito H; Higashimoto M; Atsukawa K; Ishii H
J Clin Microbiol; 2005 Jan; 43(1):186-91. PubMed ID: 15634970
[TBL] [Abstract][Full Text] [Related]
11. Serum apolipoprotein B-100 concentration predicts the virological response to pegylated interferon plus ribavirin combination therapy in patients infected with chronic hepatitis C virus genotype 1b.
Yoshizawa K; Abe H; Aida Y; Ishiguro H; Ika M; Shimada N; Tsubota A; Aizawa Y
J Med Virol; 2013 Jul; 85(7):1180-90. PubMed ID: 23918536
[TBL] [Abstract][Full Text] [Related]
12. Increase of ribavirin dose improves sustained virological response in HCV-genotype 1 patients with a partial response to peg-interferon and ribavirin.
Conti F; Vukotic R; Lorenzini S; Riili A; Cursaro C; Scuteri A; Loggi E; Galli S; Furlini G; Bernardi M; Andreone P
Ann Hepatol; 2014; 13(2):196-203. PubMed ID: 24552861
[TBL] [Abstract][Full Text] [Related]
13. Prolonged PEG-IFN and RBV is effective in patients with HCV genotype 1 and high viral load who achieved virological response later than 24 weeks.
Ueda T; Chung H; Kudo M; Ishikawa E; Hayaishi S; Tatsumi C; Inoue T; Yada N; Hagiwara S; Minami Y; Ueshima K
Intervirology; 2010; 53(1):55-9. PubMed ID: 20068342
[TBL] [Abstract][Full Text] [Related]
14. Predictive factors of early and sustained responses to peginterferon plus ribavirin combination therapy in Japanese patients infected with hepatitis C virus genotype 1b: amino acid substitutions in the core region and low-density lipoprotein cholesterol levels.
Akuta N; Suzuki F; Kawamura Y; Yatsuji H; Sezaki H; Suzuki Y; Hosaka T; Kobayashi M; Kobayashi M; Arase Y; Ikeda K; Kumada H
J Hepatol; 2007 Mar; 46(3):403-10. PubMed ID: 17126448
[TBL] [Abstract][Full Text] [Related]
15. Outcome and early viral dynamics with viral mutation in PEG-IFN/RBV therapy for chronic hepatitis in patients with high viral loads of serum HCV RNA genotype 1b.
Sasase N; Kim SR; Kudo M; Kim KI; Taniguchi M; Imoto S; Mita K; Hayashi Y; Shoji I; El-Shamy A; Hotta H
Intervirology; 2010; 53(1):49-54. PubMed ID: 20068341
[TBL] [Abstract][Full Text] [Related]
16. Predictive value of rapid virological response and early virological response on sustained virological response in HCV patients treated with pegylated interferon alpha-2a and ribavirin.
Yu JW; Wang GQ; Sun LJ; Li XG; Li SC
J Gastroenterol Hepatol; 2007 Jun; 22(6):832-6. PubMed ID: 17565637
[TBL] [Abstract][Full Text] [Related]
17. Serum proteome predicts virological response in chronic hepatitis C genotype 1b patients treated with pegylated interferon plus ribavirin.
Yen YH; Wang JC; Hung CH; Lu SN; Wang JH; Hu TH; Kee KM; Hsiao CC; Lee CM
J Formos Med Assoc; 2015 Jul; 114(7):652-8. PubMed ID: 23810703
[TBL] [Abstract][Full Text] [Related]
18. Undetectable hepatitis C virus RNA at week 4 as predictor of sustained virological response in HIV patients with chronic hepatitis C.
Martin-Carbonero L; Nuñez M; Mariño A; Alcocer F; Bonet L; García-Samaniego J; López-Serrano P; Cordero M; Portu J; Soriano V
AIDS; 2008 Jan; 22(1):15-21. PubMed ID: 18090387
[TBL] [Abstract][Full Text] [Related]
19. IFN-stimulated gene expression is a useful potential molecular marker of response to antiviral treatment with Peg-IFNα 2b and ribavirin in patients with hepatitis C virus genotype 1.
Sixtos-Alonso MS; Sánchez-Muñoz F; Sánchez-Ávila JF; Martínez RA; Domínguez López A; Vargas Vorácková F; Uribe M
Arch Med Res; 2011 Jan; 42(1):28-33. PubMed ID: 21376259
[TBL] [Abstract][Full Text] [Related]
20. Comparison of serum hepatitis C virus (HCV) RNA and core antigen levels in patients coinfected with human immunodeficiency virus and HCV and treated with interferon plus ribavirin.
Pivert A; Payan C; Morand P; Fafi-Kremer S; Deshayes J; Carrat F; Pol S; Cacoub P; Perronne C; Lunel F
J Clin Microbiol; 2006 Feb; 44(2):417-22. PubMed ID: 16455894
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]